Stay updated on GEMINI 1 Tolebrutinib Clinical Trial
Sign up to get notified when there's something new on the GEMINI 1 Tolebrutinib Clinical Trial page.

Latest updates to the GEMINI 1 Tolebrutinib Clinical Trial page
- Check5 days agoChange DetectedThe page has removed the estimated timestamps for when results were first posted and last updated, which may affect users' understanding of the timeliness of the information provided.SummaryDifference0.0%
- Check12 days agoChange DetectedThe page has been updated to reflect a modernization of the ClinicalTrials.gov data ingest expected in July 2025, with significant details about trial parameters, including treatment durations and assessment metrics for multiple sclerosis. Additionally, the expected study duration has been clarified to approximately 48 months, and specific treatment regimens have been detailed.SummaryDifference47%
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedThe page has been updated to reflect that results have now been submitted, and the revision number has changed from v2.16.1 to v2.16.2.SummaryDifference0.1%
- Check34 days agoChange DetectedThe web page has been updated to reflect a modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference0.9%
- Check62 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.0%
- Check77 days agoChange DetectedThe page has been updated to include new information about relapsing multiple sclerosis and a new registry identifier, while significant details regarding the study's objectives, duration, and inclusion/exclusion criteria have been removed.SummaryDifference23%
Stay in the know with updates to GEMINI 1 Tolebrutinib Clinical Trial
Enter your email address, and we'll notify you when there's something new on the GEMINI 1 Tolebrutinib Clinical Trial page.